Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, King JB, Bellows BK, Tajeu GS, Derington CG, Johnson J, Andrade K, Steg PG, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P. Cost-effectiveness of icosapent ethyl for high-risk patients with hypertriglyceridemia despite statin treatment. JAMA Netw Open. 2022;5(2):e2148172.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789004

Chapman MJ, Zamorano JL, Parhofer KG. Reducing residual cardiovascular risk in Europe: therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. Pharmacol Ther. 2022 Mar 15; epub ahead of print.

https://www.sciencedirect.com/science/article/abs/pii/S0163725822000663

Experimental trial research presented at the American College of Cardiology’s 71st Annual Scientific Session showed that the combinations of EPA/atorvastatin active metabolite (ATM) and of EPA/rosuvastatin (rosuva) reduced lipid oxidation by 86% and 75%, respectively (p DUBLIN, Ireland and

Kosmopoulos A, Bhatt DL, Meglis G, Verma R, Pan Y, Quan A, Teoh H, Verma M, Jiao L, Wang R, Juliano RA, Kajil M, Kosiborod MN, Bari B, Berih AA, Aguilar M, Escano A, Leung A, Coelho I, Hibino M, Díaz R, Mason RP, Steg PG, Simon T, Go AS, Ambrosy AP, Choi R, Kushner AM, Leiter LA, Al-Omran M, Verma S, Mazer CD. A randomized trial of icosapent ethyl in ambulatory patients with COVID-19. ISCIENCE. 2021; 24(9):103040.

Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Tardif JC, Verma S, Ballantyne CM; REDUCE‐IT Investigators. Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention: insights from REDUCE-IT PCI. J Am Heart Assoc. 2022; epub ahead of print.

https://www.ahajournals.org/doi/epub/10.1161/JAHA.121.022937

Singh N, Bhatt DL, Miller M, Steg G, Brinton EA, Jacobson TA, Jiao L, Tardif J-C, Mason RP, Ballantyne CM, on behalf of the REDUCE-IT Investigators. Consistency of benefit of icosapent ethyl by background statin type in REDUCE-IT. J Am Coll Cardiol. 2022;79:220-222.

Verma S, Bhatt DL, Steg G, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif J-C, Ballantyne CM, on behalf of the REDUCE-IT Investigators. Icosapent ethyl reduces ischemic events in patients with a history of previous coronary artery bypass grafting: REDUCE-IT CABG. Circulation. 2021;144:1845-1855.

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056290

Majithia A, Bhatt DL, Friedman AN, Miller M, Steg PG, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Budoff M, Mason RP, Tardif JC, Boden WE, Ballantyne CM; REDUCE-IT Investigators. Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: REDUCE-IT RENAL. Circulation. 2021;144:1750-1759.

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.055560

Marks First Health Technology Assessment (HTA) Reimbursement in Europe and Initiation of Next Phase of the Company’s Growth Strategy Company Provides Progress Update on European and International Expansion Plans DUBLIN, Ireland and BRIDGEWATER, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Amarin

Amarin-Supported Research and Analyses to Be Featured in Six Presentations DUBLIN, Ireland and BRIDGEWATER, N.J., March 21, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a diverse and full slate of supported and/or funded research on VASCEPA ® /VAZKEPA (icosapent